Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Liu D, Offin M, Harnicar S, Li BT, Drilon A

Therapeutics and Clinical Risk Management 2018, 14:1247-1252

Published Date: 20 July 2018